美罗培南联合头孢哌／／舒巴坦与米诺环素联合治疗泛耐药鲍曼不动杆菌性呼吸机相关肺炎临床观察  

Meropene and cefoperazone sulbactam associated with Minocy- cline in treatment of 48 patients with ventilator-associated pneumonia caused by pan drug-resistant Acinetobacter baumannii

作　　者：杨新良[1] 刘玮[1] 王雪松[1] 刘永安[1] 陈涵[1] 

机构地区：[1]解放军第411医院IGU,上海200081

出　　处：《麻醉与监护论坛》2014年第6期456-458,共3页Forum of Anesthesia and Monitoring

摘　　要：目的：观察美罗培南、头孢哌酮／舒巴坦、米诺环素联合治疗泛耐药鲍曼不动杆菌性呼吸机相关肺炎患者临床疗效。方法：选择泛耐药鲍曼不动杆菌性呼吸机相关肺炎患者48例，应用5％GS（NS）100ml＋美罗培南2g、静脉滴注、1次／8小时、60分钟滴入，5％GS（NS）100ml＋头孢哌酮／舒巴坦3g、静脉滴注、1次／8小时、60分钟滴入，米诺环素0．1g、鼻饲、3次／日，联合治疗10～14天，观察其临床疗效、细菌清除率、肝肾功能、C反应蛋白、降钙素原、血常规和不良反应。结果：联合抗菌治疗泛耐药鲍曼不动杆菌性呼吸机相关肺炎临床治愈率62．50％，有效率81．25％，细菌清除率62．50％：治疗过程中对肝肾功能无明显影响，无明显不良反应。结论：美罗培南、头孢哌酮／舒巴坦、米诺环素联合治疗泛耐药鲍曼不动杆菌性呼吸机相关肺炎患者效果较好。Objective. To observe the clinical effect of Meropene and cefoperazone sulbactam associated with Minocycline in treating the patients with ventilator-associated pneumonia caused by pan drug-resistant Acinetobacter baumannii（PDRAB）. Methods. 48 patients with ventilator-associated pneumonia caused by PDRAB were treated with Meropene and cefoperazone sulbactam associated with Minocycline. Results. The clinical cure rate was 62.50%,the effective rate was75%, and the clearance rate of bacteria was 62.50% after Meropene and cefoperazone sulbactam associated with Minocycline therapy. The incidence of adverse reaction was few, and it could not add liver and renal function injury. Conclusion. Meropene and cefoperazone sulbactam associated with Minocycline are effective and safe on the patients with ventilator-associated pneumonia caused by PDRAB..

关 键 词：泛耐药鲍曼不动杆菌 呼吸机相关肺炎 治疗 

分 类 号：R[医药卫生]